These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 5770131)

  • 1. Uricase inhibition in the rat by s-triazines: an animal model for hyperuricemia and hyperuricosuria.
    Johnson WJ; Stavric B; Chartrand A
    Proc Soc Exp Biol Med; 1969 May; 131(1):8-12. PubMed ID: 5770131
    [No Abstract]   [Full Text] [Related]  

  • 2. Low uricase activity in the Dalmatian dog simulated in mongrels given oxonic acid.
    Yü TF; Gutman AB; Berger L; Kaung C
    Am J Physiol; 1971 Apr; 220(4):973-9. PubMed ID: 5551153
    [No Abstract]   [Full Text] [Related]  

  • 3. [Technic of determination of serum allantoin and study of the action of uricase].
    Stahl A; Schang AM; Brogard JM; Coumaros C
    Ann Biol Clin (Paris); 1970; 28(5):377-85. PubMed ID: 5511721
    [No Abstract]   [Full Text] [Related]  

  • 4. Allantoxanamide: a potent new uricase inhibitor in vivo.
    Johnson WJ; Chartrand A
    Life Sci; 1978 Nov; 23(22):2239-44. PubMed ID: 723476
    [No Abstract]   [Full Text] [Related]  

  • 5. A short assay for the estimation of dietary purine compounds, using a rat model system with inhibition of uricase.
    Norrlind B; Kihlberg R
    J Nutr; 1973 Sep; 103(9):1262-9. PubMed ID: 4579908
    [No Abstract]   [Full Text] [Related]  

  • 6. Uric acid nephropathy in shocked rats after blocking of uricase activity with triazine compounds.
    Boda D; Pénzes P; Gecse A; Streitman K; Zsilinszky E; Karády I
    Can J Physiol Pharmacol; 1973 Jun; 51(6):496-8. PubMed ID: 4727817
    [No Abstract]   [Full Text] [Related]  

  • 7. Potent competitive uricase inhibitors--2,8-diazahypoxanthine and related compounds.
    Iwata H; Yamamoto I; Goda E; Morita K; Nakamura M
    Biochem Pharmacol; 1973 Sep; 22(18):2237-45. PubMed ID: 4733677
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors.
    Ishibuchi S; Morimoto H; Oe T; Ikebe T; Inoue H; Fukunari A; Kamezawa M; Yamada I; Naka Y
    Bioorg Med Chem Lett; 2001 Apr; 11(7):879-82. PubMed ID: 11294382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the uricase-inhibited rat as an animal model in toxicology.
    Stavric B; Nera EA
    Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase.
    Brogard JM; Coumaros D; Franckhauser J; Stahl A; Stahl J
    Rev Eur Etud Clin Biol; 1972 Nov; 17(9):890-5. PubMed ID: 4631795
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of fructose administration on serum urate levels in the uricase inhibited rat.
    Stavric B; Johnson WJ; Clayman S; Gadd RE; Chartrand A
    Experientia; 1976 Mar; 32(3):373-4. PubMed ID: 1253916
    [No Abstract]   [Full Text] [Related]  

  • 12. DKB114, A Mixture of
    Lee YS; Kim SH; Yuk HJ; Kim DS
    Nutrients; 2018 Sep; 10(10):. PubMed ID: 30274153
    [No Abstract]   [Full Text] [Related]  

  • 13. Uricostatic effect of allopurinol in the allantoxanamide-treated rat: a new method for evaluating antiuricopathic drugs.
    Hropot M; Muschaweck R; Klaus E
    Adv Exp Med Biol; 1984; 165 Pt A():175-8. PubMed ID: 6720375
    [No Abstract]   [Full Text] [Related]  

  • 14. A preliminary report of nephropathy in hyperuricemic rats.
    Waisman J; Bluestone R; Klinenberg JR
    Lab Invest; 1974 Jun; 30(6):716-22. PubMed ID: 4835598
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet aggregation in rats made hyperuricaemic with nucleic adid-rich diets containing oxonate, and inhibitor of uricase [proceedings].
    Winocour PD; Munday KA; Taylor TG; Tuner MR
    Proc Nutr Soc; 1976 Sep; 35(2):54A-55A. PubMed ID: 972878
    [No Abstract]   [Full Text] [Related]  

  • 16. [Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase].
    Royer R; Vindel J; Lamarche M; Kissel P
    Presse Med (1893); 1968 Dec; 76(49):2325-7. PubMed ID: 5737250
    [No Abstract]   [Full Text] [Related]  

  • 17. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor.
    Stavric B; Nera EA; Johnson WJ; Salem FA
    Invest Urol; 1973 Jul; 11(1):3-8. PubMed ID: 4724271
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.
    Osada Y; Tsuchimoto M; Fukushima H; Takahashi K; Kondo S; Hasegawa M; Komoriya K
    Eur J Pharmacol; 1993 Sep; 241(2-3):183-8. PubMed ID: 8243554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purine nucleotide catabolism in rat liver. Certain preliminary aspects of uricase reaction.
    Terzuoli L; Porcelli B; Ponticelli F; Marinello E
    Nucleosides Nucleotides Nucleic Acids; 2009 Mar; 28(3):193-203. PubMed ID: 19333858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
    Horiuchi H; Ota M; Kobayashi M; Kaneko H; Kasahara Y; Nishimura S; Kondo S; Komoriya K
    Res Commun Mol Pathol Pharmacol; 1999; 104(3):307-19. PubMed ID: 10741381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.